The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta‐analysis

Ding, Yangyang; Sun, Cheng; Li, Jingrong; Hu, Linhui; Li, Manman; Li, Jun; Pu, Lianfang; Xiong, Sheng

doi:10.1111/sji.12596

Cited by 42 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since an association between sPD-L1 and prognosis was demonstrated in patients with renal cell carcinoma, the prognostic implications of sPD-L1 have been suggested in several solid cancers and hematologic malignancies [25][26][27][28][29]. A meta-analysis evaluating eight studies and 1102 patients with cancers of the lung, stomach, liver, and biliary tract; lymphoma; and myeloma indicated that a higher level of sPD-L1 was associated with worse OS (HR = 1.60, 95% CI: 1.21-1.99) [30]. However, the clinical relevance of sPD-L1 in patients with PCNSL has never been reported.…”

Section: Discussionmentioning

confidence: 99%

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

et al. 2020

View full text Add to dashboard Cite

Background: The interaction of programmed death-1 protein (PD-1) and programmed death-1 ligand (PD-L1) produces immunosuppressive activity, protecting tumor cells from anti-tumor immunity and possibly releasing soluble PD-L1 (sPD-L1) from PD-L1 expressing tumor cells. Therefore, we measured serum levels of sPD-L1 in patients with primary central nervous system lymphoma (PCNSL) and explored its clinical implications. Methods: Sixty-eight patients with newly diagnosed PCNSL had diffuse large B-cell lymphoma and were treated with high-dose methotrexate-containing chemotherapy. The measurement of sPD-L1 and cytokines was performed using serum samples archived at diagnosis, and the tissue expression of PD-L1 was also analyzed from archived paraffin-embedded tissue blocks. Disease relapse, progression-free survival (PFS), and overall survival (OS) were analyzed according to the extent of sPD-L1 in serum and PD-L1 in tissue. Results: The median level of serum sPD-L1 (0.429 ng/mL) was higher than in healthy control patients (0.364 ng/mL). The occurrence of relapse was more frequent in the high sPD-L1 (78%) than the low sPD-L1 group (50%), though the groups did not have different clinical or pathological characteristics at diagnosis. As a result, the OS and PFS for the high sPD-L1 group were significantly lower than those in the low group. PD-L1-positive tumor cells were found in 35 patients (67%), and the extent of PD-L1-postive tumor cells was positively associated with serum sPD-L1 levels (r = 0.299, P = 0.031). Among the 34 cytokines analyzed, only the serum level of IL-7 correlated with the serum level of sPD-L1 (r = 0.521, P < 0.001). Conclusions: Serum levels of sPD-L1 could reflect the expression of PD-L1 in PCNSL tumor cells and predict patient survival outcomes. Therefore, sPD-L1 in serum could be a feasible biomarker for determining a risk-adapted treatment strategy for PCNSL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Serum sPD-L1, which is released from PD-L1-positive cells and binds to the PD-1 receptor, contributes to immunoregulation and can be considered a good surrogate of activation of this pathway. Moreover, sPD-L1 seems to play a role in promoting cancer cells, as was recently reported in a metaanalysis on this topic, in which it emerged as a biomarker of an unfavorable prognosis in patients with cancer 12 . Therefore, in what is likely a multistep process or a concurrent action, these mechanisms -cancer cell mutations and loss of heterozygosity on the one hand and PD-1 pathway activation on the other -participate in the complex relationship between cancer and the immune system, here represented by DM, an autoimmune disease.…”

mentioning

confidence: 55%

Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?

Labrador‐Horrillo

Selva-O’Callaghan

2018

J Rheumatol

View full text Add to dashboard Cite

“…Since an association between sPD-L1 and prognosis was demonstrated in patients with renal cell carcinoma, the prognostic implications of sPD-L1 have been suggested in several solid cancers and hematologic malignancies [25][26][27][28][29]. A meta-analysis evaluating eight studies and 1,102 patients with cancers of the lung, stomach, liver, and biliary tract; lymphoma; and myeloma indicated that a higher level of sPD-L1 was associated with worse OS (HR = 1.60, 95% CI: 1.21-1.99) [30]. However, the clinical relevance of sPD-L1 in patients with PCNSL has never been reported.…”

Section: Discussionmentioning

confidence: 99%

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Cho

Lee

Yoon

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The interaction of programmed death-1 protein (PD-1) and programmed death-1 ligand (PD-L1) produces immunosuppressive activity, protecting tumor cells from anti-tumor immunity and possibly releasing soluble PD-L1 (sPD-L1) from PD-L1 expressing tumor cells. Therefore, we measured serum levels of sPD-L1 in patients with primary central nervous system lymphoma (PCNSL) and explored its clinical implications. Methods Sixty-eight patients with newly diagnosed PCNSL had diffuse large B-cell lymphoma and were treated with high-dose methotrexate-containing chemotherapy. The measurement of sPD-L1 and cytokines was performed using serum samples archived at diagnosis, and the tissue expression of PD-L1 was also analyzed from archived paraffin-embedded tissue blocks. Disease relapse, progression-free survival (PFS), and overall survival (OS) were analyzed according to the extent of sPD-L1 in serum and PD-L1 in tissue. Results The median level of serum sPD-L1 (0.429 ng/mL) was higher than in healthy control patients (0.364 ng/mL). The occurrence of relapse was more frequent in the high sPD-L1 (78%) than the low sPD-L1 group (50%), though the groups did not have different clinical or pathological characteristics at diagnosis. As a result, the OS and PFS for the high sPD-L1 group were significantly lower than those in the low group. PD-L1-positive tumor cells were found in 35 patients (67%), and the extent of PD-L1-postive tumor cells was positively associated with serum sPD-L1 levels ( r = 0.299, P = 0.031). Among the 34 cytokines analyzed, only the serum level of IL-7 correlated with the serum level of sPD-L1 (r = 0.521, P < 0.001). Conclusions Serum levels of sPD-L1 could reflect the expression of PD-L1 in PCNSL tumor cells and predict patient survival outcomes. Therefore, sPD-L1 in serum could be a feasible biomarker for determining a risk-adapted treatment strategy for PCNSL patients.

show abstract

The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta‐analysis

Cited by 42 publications

References 28 publications

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Contact Info

Product

Resources

About